Skip to main
TMDX
TMDX logo

TMDX Stock Forecast & Price Target

TMDX Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 20%
Buy 50%
Hold 30%
Sell 0%
Strong Sell 0%

Bulls say

TransMedics Group Inc. has demonstrated robust growth metrics, particularly in the design and implementation of the Organ Care System (OCS), with donor-derived cardiac (DCD) heart transplants increasing by 15% year-over-year and DCD livers by 44% during the current quarter-to-date analysis. The company has successfully captured substantial market share within the transplant arena, benefiting from notable increases in DCD transplant volume, which has contributed to a 7% growth in the overall heart, liver, and lung market. Additionally, upcoming product launches, enhanced adoption rates for lung transplants, and anticipated improvements in operating margins present significant potential for revenue growth, supporting positive projections for future revenue performance.

Bears say

TransMedics Group Inc. has experienced a decline in donor brain death (DBD) organs, with a 6% year-over-year and 13% month-over-month drop for livers, alongside a 6% year-over-year and 12% month-over-month decrease for hearts, which raises concern about the company's market position. Although there was a year-over-year growth in donor circulatory death (DCD) organs for livers and hearts, the overall trends show total DBD organ volumes have decreased by 2% quarter-over-quarter, suggesting potential challenges in sustaining growth. Furthermore, factors such as increasing competition, disappointing adoption rates for their Organ Care System, and possible reimbursement changes add to the negative outlook for TransMedics Group's future performance.

TMDX has been analyzed by 10 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 50% recommend Buy, 30% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Transmedics Group Inc (TMDX) Forecast

Analysts have given TMDX a Buy based on their latest research and market trends.

According to 10 analysts, TMDX has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $120.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $120.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Transmedics Group Inc (TMDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.